natgillin/translations-raw huggingface dataset:
The fifth study compared Rxulti with placebo over one year, and the main measure of effectiveness was the risk of relapse (worsening of symptoms). 
V peti študiji so primerjali zdravilo Rxulti s placebom za obdobje enega leta, pri čemer je bilo glavno merilo učinkovitosti tveganje za pojav ponovitve (poslabšanje simptomov).
Rxulti was effective at reducing symptoms of schizophrenia. 
Zdravilo Rxulti je bilo učinkovito pri zmanjševanju simptomov shizofrenije.
What are the risks associated with Rxulti? 
Kakšna tveganja so povezana z zdravilom Rxulti?
What is Rxulti and what is it used for? 
Kaj je zdravilo Rxulti in za kaj se uporablja?
These neurotransmitters play a role in schizophrenia, and by acting at their receptors, brexpiprazole helps normalise the activity of the brain and reduce symptoms of schizophrenia. 
Brekspiprazol z delovanjem na njihove receptorje pomaga normalizirati delovanje možganov in zmanjšuje simptome shizofrenije.
The most common side effects with Rxulti are akathisia (a constant urge to move, which may affect around 6 in 100 people) and weight gain (which may affect around 4 in 100 people). 
Najpogostejša neželena učinka zdravila Rxulti sta akatizija (neprestana potreba po gibanju, ki se lahko pojavi pri približno 6 od 100 bolnikov) in povečanje telesne mase (ki se lahko pojavi pri približno 4 od 100 bolnikov).
Results at 2, 3 and 4 weeks showed improvement in symptoms with Rxulti compared with placebo. 
Rezultati pri dveh, treh in štirih tednih so pokazali izboljšanje simptomov pri uporabi zdravila Rxulti v primerjavi s placebom.
After 6 weeks, there was not considered to be a difference between Rxulti and placebo. 
Po šestih tednih ni bilo mogoče zaznati razlike med zdravilom Rxulti in placebom.
The dose is then increased to 2 mg once daily taken on days 5, 6 and 7 and increased again if necessary to 4 mg once daily on day 8. 
Odmerek se nato poveča na 2 mg enkrat na dan od 5. do 7. dne, nato pa se 8. dan po potrebi znova poveča, in sicer na 4 mg enkrat na dan. Priporočeni odmerek je od 2 do 4 mg na dan, največji priporočeni dnevni odmerek pa je 4 mg.
In the fourth study, doses of Rxulti ranging from 2 to 4 mg were compared with placebo and with another antipsychotic medicine, quetiapine. 
V četrti študiji so primerjali odmerke zdravila Rxulti v razponu od 2 do 4 mg s placebom in z drugim antipsihotičnim zdravilom, kvetiapinom.
For the full list of side effects and restrictions with Rxulti, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Rxulti glejte navodilo za uporabo.
How is Rxulti used? 
Kako se zdravilo Rxulti uporablja?
Quetiapine showed improvement in symptoms at 6 weeks compared with placebo. 
V primerjavi s placebom je uporaba kvetiapina pokazala izboljšanje simptomov pri šestih tednih.
Rxulti has been shown to be effective at reducing symptoms of schizophrenia in 5 main studies involving 2,404 adults with schizophrenia, although there were some inconsistent results. 
V petih glavnih študijah, ki so vključevale 2 404 odrasle s shizofrenijo, se je pokazalo, da je zdravilo Rxulti učinkovito pri zmanjševanju simptomov shizofrenije, čeprav je bilo med rezultati nekaj neskladja.
How does Rxulti work? 
Kako zdravilo Rxulti deluje?
Rxulti can only be obtained with a prescription. 
Predpisovanje in izdaja zdravila Rxulti je le na recept.
In the third study, the PANSS score fell by around 15 points with 2 mg Rxulti compared with 8 points with placebo and there was not considered to be a difference between 4 mg Rxulti and placebo. 
V tretji študiji se je ocena po lestvici PANSS zmanjšala za približno 15 točk pri odmerku 2 mg zdravila Rxulti v primerjavi z 8 točkami pri placebu, med odmerkom 4 mg zdravila Rxulti in placebom pa ni bilo mogoče zaznati razlike.
In the first study, the PANSS score fell by around 21 and 20 points with 2 mg and 4 mg Rxulti respectively compared with 12 points with placebo. 
V prvi študiji se je ocena po lestvici PANSS zmanjšala za približno 21 oziroma 20 točk pri odmerkih 2 oziroma 4 mg zdravila Rxulti v primerjavi z 12 točkami pri placebu.
In the second study, the PANSS score fell by around 20 points with 4 mg Rxulti compared with 14 points with placebo. 
V drugi študiji se je ocena po lestvici PANSS zmanjšala za približno 20 točk pri odmerku 4 mg zdravila Rxulti v primerjavi s 14 točkami pri placebu.
Rxulti contains the active substance brexpiprazole. 
Zdravilo Rxulti vsebuje učinkovino brekspiprazol.
However, there was not considered to be a difference between 2 mg Rxulti and placebo. 
Med odmerkom 2 mg zdravila Rxulti in placebom pa ni bilo mogoče zaznati razlike.
Annex I List of medicinal products and presentations 
PRILOGA I SEZNAM NACIONALNO ODOBRENIH ZDRAVIL
This summary was last updated on 30 August 2007. 
Ta povzetek je bil nazadnje posodobljen 30. avgusta 2007.
These reactions should disappear within two to three days. 
Te reakcije izginejo v dveh do treh dneh.
Only healthy dogs should be vaccinated. 
Cepiti smemo samo zdrave pse.
If you want more information on the basis of the CVMP recommendations, read the Scientific Discussion (also part of the EPAR). 
Če želite več informacij o podlagi za priporočila CVMP, preberite znanstveno razpravo (ki je prav tako del
This document cannot replace a face-to-face discussion with your veterinarian. 
Ta dokument ne more nadomestiti neposrednega pogovora z veterinarjem.
In general, these disappear within four days, but in rare cases they can persist for up to 14 days after the second injection. 
Te običajno izginejo v štirih dneh, v redkih primerih ostanejo do 14 dni po drugi injekciji.
This helps to reduce the symptoms of babesiosis. 
To prispeva k zmanjšanju simptomov babezioze.
The vaccine also contains an ‘adjuvant' (a compound called saponin) to stimulate a better response. 
Cepivo vsebuje tudi adjuvans (spojino saponin) za stimulacijo boljšega odziva.
It is recommended that the vaccination is given at least one month before the tick season and exposure to ticks be reduced during the vaccination period. 
Priporočljivo je, da se cepljenje izvede najmanj en mesec pred sezono klopov ter da se v času cepljenja izpostavljenost klopom zmanjša.
Re-vaccination is achieved with a single injection every six months. 
Obnovitveno cepljenje se izvaja s posameznimi injekcijami vsakih šest mesecev.
If mild symptoms occur and last for more than two days, veterinary advice should be sought. 
Če se pojavijo blagi simptomi, ki trajajo več kot dva dni, je potreben posvet z veterinarjem.
Nobivac Piro is a vaccine. 
Zdravilo Nobivac Piro je cepivo.
Dogs that are infected with B. canis but have no symptoms should be treated appropriately before vaccination. 
Pse, ki so okuženi z B. canis, vendar nimajo simptomov, je treba pred cepljenjem ustrezno zdraviti.
When a dog is given the vaccine, the immune system recognises the antigens as ‘foreign' and makes antibodies against them. 
Ko pes dobi cepivo, imunski sistem prepozna antigene kot tujke in tvori protitelesa proti njim.
EPAR summary for the public 
NOBIVAC PIRO Povzetek EPAR za javnost
Immunity starts three weeks after the vaccination course and lasts for at least six months. 
Imunost nastopi tri tedne po osnovnem cepljenju in traja najmanj šest mesecev.
If accidental self-injection occurs, seek medical advice immediately and show the Package Leaflet or the label to the doctor. 
V primeru nenamernega samoinjiciranja nemudoma poiščite medicinsko pomoč in pokažite zdravniku Navodilo za uporabo ali nalepko.
The main measure of effectiveness was the proportion of the dogs that developed antibodies against B. canis and B. rossi two weeks after the second injection. 
Glavno merilo učinkovitosti je bil delež psov, pri katerih so se razvila protitelesa proti B. canis in B. rossi dva tedna po drugi injekciji.
Vaccination with Novibac Piro does not prevent infection, so a milder form of disease caused by B. canis can occur. 
Cepljenje z zdravilom Nobivac Piro ne prepreči okužbe, zato lahko pride do milejše oblike bolezni, ki jo povzroča B. canis.
The European Commission granted a marketing authorisation valid throughout the European Union for Nobivac Piro to Intervet International B.V. on 2 September 2004. 
Evropska Komisija je dovoljenje za promet z zdravilom Nobivac Piro, veljavno po vsej Evropski uniji, odobrila družbi Intervet International B.V.
Because the antigens on B. canis are very variable, vaccines against B. canis only work effectively if they also include antigens from B. rossi. 
Ker so antigeni iz vrste B. canis zelo raznoliki, so cepiva proti B. canis učinkovita samo, če vključujejo tudi antigene iz vrste B. rossi.
For initial vaccination, Nobivac Piro is given as two 1-ml injections under the skin three to six weeks apart. 
Pri osnovnem cepljenju se zdravilo Nobivac Piro daje v obliki dveh 1 ml injekcij pod kožo v razmiku treh do šestih tednov.
Side effects such as lethargy (listlessness) and a reduction in appetite are also common, sometimes accompanied by fever and a stiff gait. 
Pogosti so tudi neželeni učinki, kot sta zaspanost (ravnodušnost) in zmanjšanje teka, ki jih včasih spremlja povišana telesna temperatura in toga hoja.
Other information about Nobivac Piro: 
Druge informacije o zdravilu Nobivac Piro:
The effectiveness of Nobivac Piro has been studied in three laboratory studies in which dogs were vaccinated and then challenged (exposed to wild type Babesia). 
Učinkovitost zdravila Nobivac Piro so preučevali v treh laboratorijskih raziskavah, v katerih so pse najprej cepili, nato pa jih izpostavili (divjemu tipu zajedavca Babesia).
The benefit-risk balance may be found in module 6 of this EPAR. 
Razmerje med koristmi in tveganji najdete v modulu 6 tega evropskega javnega poročila o oceni zdravila
What benefit has Nobivac Piro shown during the studies? 
Kakšne koristi je zdravilo Nobivac Piro izkazalo med raziskavami?
Nobivac Piro was more effective than placebo at stimulating the production of antibodies: more dogs receiving the vaccine developed antibodies than those receiving placebo. 
Zdravilo Nobivac Piro je bilo pri stimulaciji tvorbe protiteles učinkovitejše od placeba: protitelesa je tvorilo več psov, ki so prejemali cepivo, kot psov, ki so prejemali placebo.
Information on the prescription status of this product may be found on the label/outer package. 
Podatki o predpisovanju tega zdravila so navedeni na nalepki na škatli zdravila.
The effects of vaccination were compared with those of vaccination using a placebo (a dummy treatment). 
Učinke cepljenja so primerjali z učinki cepljenja s placebom.
After vaccination, painful swelling or hardened nodules occur commonly at the site of vaccination. 
Po cepljenju na mestu cepljenja pogosto nastanejo boleče otekline ali zatrdline.
Nobivac Piro is a vaccine that contains antigens (proteins) from the parasites Babesia canis and Babesia rossi. 
Zdravilo Nobivac Piro je cepivo, ki vsebuje antigene (beljakovine) zajedavcev Babesia canis in Babesia rossi.
In the future, the immune system will be able to produce antibodies more quickly when it is again exposed to B. canis. 
Ko bo imunski sistem naslednjič izpostavljen B. canis, bo lahko hitreje izdelal protitelesa.
What is the risk associated with Nobivac Piro? 
Kakšna tveganja so povezana z zdravilom Nobivac Piro?
Nobivac Piro is a lyophilisate (freeze-dried pellet) and solvent that are made up into a suspension for injection. 
Zdravilo Nobivac Piro je liofilizat (peleta, posušena v zmrznjenem stanju) in vehikel za pripravo suspenzije za injiciranje.
Nobivac Piro should not be used in bitches that are pregnant or lactating. 
Zdravila Nobivac Piro se ne sme uporabljati pri brejih psicah ali psicah v laktaciji.
Why has Nobivac Piro been approved? 
Zakaj je bilo zdravilo Nobivac Piro odobreno?
Nobivac Piro is used to vaccinate dogs aged six months or older against B. canis, a protozoan (single-celled organism) transmitted by ticks that lives in red blood cells. 
Zdravilo Nobivac Piro se uporablja za cepljenje psov, starih šest mesecev ali več, proti zajedavcu B. canis, protozoju (enoceličarju), ki ga prenašajo klopi in živi v rdečih krvnih celicah.
The vaccine can reduce the severity of symptoms caused by acute (short-lived) babesiosis (the disease caused by infection with B. canis, with weakness, fever and jaundice) and anaemia (low red blood cell counts). 
babezioza (bolezen, ki jo povzroča okužba z B. canis in jo spremljajo šibkost, povišana telesna temperatura in zlatenica) in anemija (nizka koncentracija rdečih krvnih celic).
What is Nobivac Piro used for? 
Za kaj se zdravilo Nobivac Piro uporablja?
Further one main field study was performed, including dogs of at least six months of age of various breeds who received two injections of Nobivac Piro three weeks apart. 
stari najmanj šest mesecev, ki so prejeli dve injekciji zdravila Nobivac Piro v razmiku treh tednov.
Nobivac Piro contains small amounts of antigens (soluble parasite antigens) from B. canis and the related species B. rossi that have been extracted from cultures of the parasites in red blood cells. 
Zdravilo Nobivac Piro vsebuje majhne količine antigenov (topnih parazitskih antigenov) zajedavca B. canis in sorodne vrste B. rossi,
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Nobivac Piro exceed the risks for active immunisation of dogs of six months or older against B. canis to reduce the severity of clinical signs associated with acute babesiosis (B. canis) and anaemia as measured by packed cell volume, and recommended that Nobivac Piro be given a marketing authorisation. 
Nobivac Piro pri aktivni imunizaciji psov, starih šest mesecev ali več, proti B. canis z namenom zmanjšanja resnosti kliničnih znakov, povezanih z akutno babeziozo (B. canis) in anemijo, določeno s hematokritom, večje od z njim povezanih tveganj.
How does Nobivac Piro work? 
Kako zdravilo Nobivac Piro deluje?
What is Nobivac Piro? 
Kaj je zdravilo Nobivac Piro?
This overview was last updated in 06-2018. 
Pregled je bil nazadnje posodobljen 06-2018.
For these patients other treatment options should be considered. 
Pri teh bolnikih je treba razmisliti o drugih možnostih zdravljenja.
The majority of side effects are mild and short-lived. 
Večina neželenih učinkov je blagih in kratkotrajnih.
Regarding safety, side effects were mostly mild and transient, but it was recommended that the longterm safety of the medicine be further investigated. 
Kar zadeva varnost, so bili neželeni učinki večinoma blagi in prehodni, vendar pa je bilo priporočeno, da se dolgoročna varnost zdravila nadalje prouči.
What measures are being taken to ensure the safe and effective use of Cerdelga? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Cerdelga?
The European Medicines Agency decided that Cerdelga's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Cerdelga večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Further information on Cerdelga can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Nadaljnje informacije za zdravilo Cerdelga so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
All patients switching from enzyme replacement should be regularly monitored for disease progression. 
Pri vseh bolnikih, ki preidejo z nadomestnega encimskega zdravljenja, je treba redno spremljati napredovanje bolezni.
Patients who break down the medicine at normal speed take 1 capsule twice a day, while those who break down the medicine slowly take 1 capsule once a day. 
Bolniki, pri katerih se zdravilo razgrajuje z normalno hitrostjo, jemljejo eno kapsulo dvakrat na dan, bolniki, pri katerih se zdravilo razgrajuje počasi, pa jemljejo eno kapsulo enkrat na dan.
Cerdelga received a marketing authorisation valid throughout the EU on 19 January 2015. 
Za zdravilo Cerdelga je bilo 19. januarja 2015 izdano dovoljenje za promet, veljavno po vsej EU.
The most common serious side effect is fainting, in 8 out of every 1,000 patients. 
Najpogostejši resni neželeni učinek je omedlevica; ta se lahko pojavi pri 8 od 1 000 bolnikov.
Before starting treatment, the patient is tested to see how rapidly their bodies break down the medicine. 
Pred začetkom zdravljenja je treba pri bolniku preveriti, kako hitro se zdravilo v njegovem telesu razgrajuje.
The company will also keep record of patients treated with Cerdelga to look at the long-term safety of the medicine. 
Podjetje bo tudi vodilo evidenco bolnikov, zdravljenih z zdravilom Cerdelga, da bo proučilo dolgoročno varnost zdravila.
Patients who have not been tested or whom results of the test are not clear should also not take this medicine. 
Prav tako ga ne smejo jemati bolniki, pri katerih test ni bil opravljen ali rezultati testa niso jasni.
Other information about Cerdelga 
Druge informacije o zdravilu Cerdelga
Cerdelga is available as capsules (84 mg) to be taken by mouth. 
Zdravilo Cerdelga je na voljo v obliki kapsul (84 mg), ki se jemljejo peroralno.
As for all medicines, data on the use of Cerdelga are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Cerdelga stalno spremljajo.
In this study, the disease remained stable in 85% of patients who switched to Cerdelga for a year and in 94% of patients who continued with enzyme replacement therapy. 
V tej študiji je bolezen ostala stabilna pri 85 % bolnikov, ki so za eno leto prešli na zdravilo Cerdelga, in pri 94 % bolnikov, ki so nadaljevali nadomestno encimsko zdravljenje.
Cerdelga is a medicine used for the long-term treatment of type-1 Gaucher disease in adults. 
Cerdelga je zdravilo, ki se uporablja za dolgotrajno zdravljenje Gaucherjeve bolezni tipa 1 pri odraslih.
What benefits of Cerdelga have been shown in studies? 
Kakšne koristi zdravila Cerdelga so se pokazale v študijah?
An overview of Cerdelga and why it is authorised in the EU 
Pregled zdravila Cerdelga in zakaj je odobreno v EU
Why is Cerdelga authorised in the EU? 
Zakaj je bilo zdravilo Cerdelga odobreno v EU?
Gaucher disease is rare, and Cerdelga was designated an ‘orphan medicine' (a medicine used in rare diseases) on 4 December 2007. 
Gaucherjeva bolezen je redka, zato je bilo zdravilo Cerdelga 4. decembra 2007 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
The disease is caused by the lack of an enzyme for breaking down fat. 
Bolezen povzroča pomanjkanje encima za razgradnjo maščobe.
Cerdelga must not be taken by some patients with liver problems or those taking certain medicines that can interfere with the ability of the body to break down the medicine. 
Zdravila Cerdelga ne smejo jemati nekateri bolniki s težavami z jetri ali bolniki, ki jemljejo določena zdravila, ki lahko vplivajo na sposobnost telesa za razgradnjo zdravila.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cerdelga have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Cerdelga upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Side effects reported with Cerdelga are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Cerdelga, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Patients who took Cerdelga also showed an improvement of other signs of the disease such as a reduction in liver size and increased levels of haemoglobin (the protein in red blood cells that carries oxygen). 
Pri bolnikih, ki so jemali zdravilo Cerdelga, so se poleg tega izboljšali tudi drugi znaki bolezni, saj je na primer prišlo do zmanjšanja velikosti jeter in zvišanja ravni hemoglobina (beljakovine v rdečih krvnih celicah, ki prenaša kisik).
Patients whose bodies break down this medicine very rapidly (‘ultrarapid metabolisers') should not take Cerdelga. 
Bolniki, pri katerih se zdravilo razgrajuje zelo hitro („zelo hitri presnavljalci“), zdravila Cerdelga ne smejo jemati.
Another study looked at Cerdelga in 159 patients whose disease was well controlled by enzyme replacement therapy. 
V drugi študiji so zdravilo Cerdelga preučevali pri 159 bolnikih, katerih bolezen je bila dobro obvladana z nadomestnim encimskim zdravljenjem.
For more information about using Cerdelga, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Cerdelga glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
This causes symptoms such as anaemia (low red blood cell counts), tiredness, easy bruising, an enlarged spleen and liver, and bone pain and fractures. 
To povzroča simptome, kot so anemija (nizko število rdečih krvnih celic), utrujenost, pogosto nastajanje modric, povečana vranica in jetra, bolečine v kosteh ter zlomi kosti.
Gaucher disease is a genetic condition, in which a fat called glucosylceramide (or glucocerebroside) builds up in the body, typically in the liver, spleen and bone. 
Gaucherjeva bolezen je genska bolezen, pri kateri se maščoba, imenovana glukozilceramid (ali glukocerebrozid), kopiči v telesu, predvsem v jetrih, vranici in kosteh.
What is Cerdelga and what is it used for? 
Kaj je zdravilo Cerdelga in za kaj se uporablja?
What are the risks associated with Cerdelga? 
Kakšna tveganja so povezana z zdravilom Cerdelga?
The company that markets Cerdelga will provide doctors and patients with educational materials to ensure that only patients with type-1 Gaucher disease are treated with Cerdelga and that Cerdelga is not used in some patients with liver problems and together with other medicines which can significantly alter its blood levels. 
Podjetje, ki trži zdravilo Cerdelga, bo zdravnikom in bolnikom priskrbelo izobraževalno gradivo, da zagotovi, da bodo zdravilo Cerdelga prejemali samo bolniki z Gaucherjevo boleznijo tipa 1 in da se to zdravilo ne bo uporabljajo pri nekaterih bolnikih s težavami z jetri in skupaj z drugimi zdravili, ki lahko bistveno spremenijo ravni zdravila Cerdelga v krvi.
The active substance in Cerdelga, eliglustat, works by blocking the action of an enzyme involved in the production of the glucosylceramide fat. 
Učinkovina zdravila Cerdelga, eliglustat, deluje tako, da zavira encim, ki sodeluje pri tvorbi glukozilceramida.
The most common side effect seen with Cerdelga is dyspepsia (heartburn) in approximately 6 out of 100 patients. 
Najpogostejši neželeni učinek, opažen pri zdravilu Cerdelga, je dispepsija (zgaga); pojavi se lahko pri približno 6 od 100 bolnikov.
In a study of 40 previously untreated patients with type-1 Gaucher disease, patients taking Cerdelga had a 28% reduction in spleen size, compared with a 2% increase in those taking placebo (a dummy treatment) after 9 months of treatment. 
V študiji s 40 predhodno nezdravljenimi bolniki z Gaucherjevo boleznijo tipa 1 se je po devetih mesecih zdravljenja pri bolnikih, ki so jemali zdravilo Cerdelga, velikost vranice zmanjšala za 28 %, pri bolnikih, ki so jemali placebo (zdravilo brez učinkovine), pa se je povečala za 2 %.
Cerdelga can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in the management of Gaucher disease. 
Predpisovanje in izdaja zdravila Cerdelga je le na recept, zdravljenje z njim pa mora uvesti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem Gaucherjeve bolezni.
Studies show that Cerdelga is effective at treating the disease, including reducing the size of enlarged spleens and livers. 
Študije so pokazale, da zdravilo Cerdelga učinkovito zdravi bolezen in zmanjšuje velikost povečane vranice in jeter.